Two chemotherapy sequences for elderly double expressor DLBCL
Part of Cancer clinical trials.
This trial tests a new sequence of two chemotherapy regimens (RLC followed by CR-CHOP) for elderly patients with a fast-growing DLBCL called double expressor lymphoma. The goal is to see if this approach is safe and effective for people who may not tolerate standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with untreated DLBCL (a type of lymphoma).
- Your biopsy must show high levels of both MYC and BCL2 proteins (called 'double expressor').
- You are over 70, or at least 65 with some difficulty in daily activities (ECOG 2+).
- You have at least one tumor that can be measured (a lymph node >1.5 cm or other tumor >1 cm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
This study tests a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) for older adults newly diagnosed with a certain type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this combination is safe and effective for people who may not be able to handle standard, more intense chemotherapy.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.